Title: Effects of Lipid-Lowering Drugs on Adiponectin
Volume: 8
Issue: 6
Author(s): Apostolos Perelas, Anna Tsoulkani and Despina Perrea
Affiliation:
Keywords:
Adiponectin, hypolipidaemic drugs, statins, omega-3 fish oils, niacin, fibrates, sterols, ezetimibe, Lipid-Lowering Drugs, coronary heart disease, diabetes, insulin resistance, plant sterols, peroxisome proliferator-activator receptor, omega-3 fatty acids, bezafibrate primarily, coronary artery disease, bile acids sequestrants, probucol, nitric oxide, reactive oxygen species, fibrinolysis, adipoQ, GBP28, atorvastatin, pitavastatin, flu-vastatin, simvastatin, pravastatin, rosuvastatin, fibrates, fenofibrate, bezafibrate, gemfibrozil, ciprofibrate, nicotinic acid, stanols, T-cadherin, Hypoadiponect-inaemia, dyslipidaemia, hyperadiponectinaemia, leptin, resistin, apelin, visfatin, vaspin, hepcidine, chemerin, omentin, plasminogen activator inhibitor, tumour necrosis factor, vascular remodelling, West of Scotland Coronary Prevention Study, athero-genesis, proliferated-activator receptor gamma 2, phospholipase 2, 15-deoxy-delta 12, 14-prostaglandin J2, Oxidative Stress
Abstract: Adiponectin has been implicated in the pathogenesis of coronary heart disease. We review the literature describing the effect of lipid-lowering agents on adiponectin bioavailability. Statins exert variable effects that can be influenced by patient-dependent characteristics (i.e. diabetes or insulin resistance). Fibrates and especially niacin can raise adiponectin levels. The impact of plant sterols, ezetimibe and ω-3 fish oils on adiponectin in humans remains to be defined.There was no literature on whether resins can alter adiponectin levels.
As far as mechanisms are concerned, statins enhance peroxisome proliferator-activator receptor (PPAR)-γ activation and have antioxidant or anti-inflammatory potential. Niacin, ω-3 fatty acids, plant sterols and bezafibrate primarily act by increasing PPAR-γ activity and possibly by reducing oxidative stress or inflammation. Both fibrates and ω-3 fish oils act as synthetic ligands for PPAR-α.
Hypolipidaemic drugs can affect adiponectin bioavailability, although the impact depends on the individual drug administered and patient characteristics. However, with the exception of niacin, the results observed are not conclusive.
